SYMBIO PHARMACEUTICALS LIMITED

Press Releases SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Delayed Japan Exchange Other stock markets 22:30:00 2024-07-01 EDT			5-day change	1st Jan Change
161 ^JPY	-0.62%		-1.23%	-34.82%

05-07	Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024	CI
04-19	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	23-03-16	AQ
SymBio Pharmaceuticals : Revision to Earnings Forecast for FY 2022	22-08-04	PU
SymBio Pharmaceuticals : Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 (Consolidated)	22-08-04	PU
Adenovirus Infections Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight \| Tianjin CanSino Biotechnology, Kuur therapeutics, AlloVir, SymBio Pharmaceuticals and Others.	21-05-12	AQ
Eagle Pharmaceuticals : Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute Formulation, with Launch Expected in January 2021	20-09-24	AQ
Eagle Pharmaceuticals : Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM Rapid Infusion Liquid Bendamustine Formulation	20-03-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer